UNH news: sellers remain in control with oversold RSI and no bullish divergence

Traders Union
All News
Financial News
Unitedhealth group slides 1.35% today

Highlights

UnitedHealth Group (UNH) closed at $317.23 after a 1.35% daily drop, trading below all key moving averages with persistent downside momentum.
The company reported third-quarter earnings of $2.92 per share, 12.2% revenue growth to $113.16 billion, and raised its 2025 full-year earnings outlook.
Bearish technicals prevail as RSI hits 29.45 and no bullish divergence forms, indicating a sub-20% rebound probability and likely further downside below $316.73 support.

Upbeat earnings and guidance boost, as institutions increase share retention

UnitedHealth Group has declared a quarterly dividend of $2.21 per share, payable on December 16, 2025, to shareholders of record as of December 8, 2025. The company achieved third-quarter earnings of $2.92 per share, exceeding consensus estimates, with revenue increasing 12.2% year-over-year to $113.16 billion. UnitedHealth also reported a return on equity of 19.23%, a net margin of 4.04%, and raised its full-year earnings outlook for 2025, while institutional investors and hedge funds collectively hold about 87.86% of its shares.

Bearish dominance confirmed as momentum indicators flash deep oversold levels

Momentum indicators confirm strong bearish sentiment for UNH. The price remains under all key moving averages, with the Ichimoku Kijun at $351.28 serving as the nearest dynamic resistance. MACD and ADX indicate downside dominance, while deeply oversold readings from RSI (29.45), Stoch RSI (0.00), and CCI (–167.86) suggest selling exhaustion. BBP and the Awesome Oscillator reinforce the ongoing downtrend, with selling pressure persisting as the price trades near today’s low in the $316.73 – $320.34 range and no bullish divergence present.

Low rebound odds as downside risks outweigh breakout potential

For the upcoming week, the projected trading range for UNH is $330.37 to $332.72. There is a very low probability (less than 20%) of a sustained price rebound, and the prevailing scenario calls for sideways consolidation below key resistance levels. Should bullish momentum ignite and a breakout above $351.28 (Ichimoku Kijun) occur, further upside toward the $330 – $332 corridor could be seen. However, continued downside is more likely, with a breakdown below current support increasing the risk of new lows and potentially accelerating the ongoing downtrend.

Viktoras Karapetjanc, expert at Traders Union, notes that despite UnitedHealth Group’s robust fundamentals—including a strong return on equity, institutional support, and upgraded earnings outlook—the technical landscape remains challenging, with the stock trading well below all key moving averages and indicators signaling persistent bearish momentum. He highlights that while recent fundamental achievements point to underlying corporate strength, current market sentiment and technical exhaustion have yet to translate into sustained price recovery. Nonetheless, Karapetjanc sees institutional backing and positive earnings trends as potential catalysts for a turnaround once selling pressure subsides. "In my view, the ongoing bearish phase presents a constructive setup for patient investors, as UnitedHealth’s solid fundamentals could offer a strong foundation for recovery once technical headwinds ease," he concludes.

Previously, it was noted that persistent downside momentum dominates technicals, with UNH maintaining a position well below key short-, medium-, and long-term moving averages. Recent analysis highlighted that further downside risk builds as rebound chances stay limited, particularly as technical signals indicate oversold conditions and bearish sentiment.

Source of Data: UNH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.